Literature DB >> 656779

Early deaths in Jamaican children with sickle cell disease.

D W Rogers, J M Clarke, L Cupidore, A M Ramlal, B R Sparke, G R Serjeant.   

Abstract

In Jamaican children with homozygous sickle cell (SS) disease diagnosed at birth two-year survival was 87%, compared with 95% in children with sickle cell-haemoglobin C (CS) disease, and 99% in normal controls. Death among those with SS disease occurred most often between the ages of 6 and 12 months. Principal causes were acute splenic sequestration and pneumococcal infection. Neonatal diagnosis of haemoglobinopathies must be followed by close observation if mortality is to be reduced by early diagnosis and treatment of these complications.

Entities:  

Mesh:

Year:  1978        PMID: 656779      PMCID: PMC1605039          DOI: 10.1136/bmj.1.6126.1515

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  4 in total

1.  Natural history of sickle cell disease--the first ten years.

Authors:  D R Powars
Journal:  Semin Hematol       Date:  1975-07       Impact factor: 3.851

2.  Screening cord bloods for detection of sickle cell disease in Jamaica.

Authors:  B E Serjeant; M Forbes; L L Williams; G R Serjeant
Journal:  Clin Chem       Date:  1974-06       Impact factor: 8.327

3.  Acute splenic sequestration crises (ASSC) in young children with sickle cell anemia. Clinical observations in 20 episodes in 14 children.

Authors:  R A Seeler; M Z Shwiaki
Journal:  Clin Pediatr (Phila)       Date:  1972-12       Impact factor: 1.168

4.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  4 in total
  41 in total

1.  Splenectomy and acute splenic sequestration crises in sickle cell disease.

Authors:  A H Al Salem; S Qaisaruddin; Z Nasserullah; I Al Dabbous; H Abu Srair; A Al Jam'a
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

2.  Acute splenic sequestration crisis in a young woman with homozygous sickle cell anaemia.

Authors:  P S Sarma
Journal:  Postgrad Med J       Date:  1989-02       Impact factor: 2.401

Review 3.  Malaria chemoprophylaxis in sickle cell disease.

Authors:  O Oniyangi; A A A Omari
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

4.  A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations.

Authors:  I B Sardharwalla; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Authors:  Susan T Paulukonis; James R Eckman; Angela B Snyder; Ward Hagar; Lisa B Feuchtbaum; Mei Zhou; Althea M Grant; Mary M Hulihan
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

6.  Partial splenectomy in sickle cell syndromes.

Authors:  A Nouri; M de Montalembert; Y Revillon; R Girot
Journal:  Arch Dis Child       Date:  1991-09       Impact factor: 3.791

7.  Current sickle cell screening program for newborns in New York City, 1979-1980.

Authors:  R Grover; S Shahidi; B Fisher; D Goldberg; D Wethers
Journal:  Am J Public Health       Date:  1983-03       Impact factor: 9.308

8.  Sickle cell disease in Saudi Arabs in early childhood.

Authors:  R P Perrine; P John; M Pembrey; S Perrine
Journal:  Arch Dis Child       Date:  1981-03       Impact factor: 3.791

9.  Bone marrow transplantation in sickle cell anaemia.

Authors:  C Vermylen; G Cornu; M Philippe; J Ninane; A Borja; D Latinne; A Ferrant; J L Michaux; G Sokal
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

10.  Defective yeast opsonisation and functional deficiency of complement in sickle cell disease.

Authors:  V F Larcher; R J Wyke; L R Davis; C E Stroud; R Williams
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.